Endocrinology

Elena Christofides, MD, discusses the interim results of CAPTAIN-T2D, a trial that plans to evaluate clofutriben’s efficacy in these patients.

Elif Oral, MD, discusses the clinical implications of the recent data emphasizing metreleptin’s anti-drug antibodies and their llack of impact on efficacy.

ENDO 2026 data suggest tirzepatide may improve renal transplant eligibility in patients with T2D, CKD, and severe obesity.

Elif Oral, MD, discusses her recent presentation at ENDO 2026 covering a phase 4 trial of the immunogenicity of metreleptin in this rare disease.

At ENDO 2026, findings suggest SBP reductions in adults with diabetes are driven by weight loss, not GLP-1 therapy type.

New data presented at ENDO 2026 have indicated substantially lower basal insulin and bolus insulin dose requirements in this population following discharge.

At ENDO 2026, persistent symptoms in hypothyroidism may reflect non-thyroid causes, underscoring the need for broader clinical evaluation

At ENDO 2026, persistent fatigue and brain fog despite normal thyroid labs underscored the need for individualized care.

Greater BMI reduction with semaglutide in adolescents with severe obesity was tied to improved triglycerides, TG/HDL ratio, and HbA1c

Analysis of plasma EVs identified 448 proteins associated with islet autoimmunity and potential early T1D biomarkers.

Alan Hutchison, MD, PhD, and Mishal Ali discuss the substantially increased risk of long-term mortality caused by diabetes in patients undergoing major organ transplants.

New systematic review of 7012 kidney transplant recipients with T2D finds GLP-1 receptor agonists cut major adverse kidney events and mortality by 61%.

New data from ENDO 2026 reflect the accompanying reductions in HbA1c, lipids, and other major biomarkers in patients treated with GLP-1 RAs.

New data from ENDO 2026 have indicated a statistically significant increase in hypotension and related events in adults receiving GLP-1s who are already hypertensive.

MiniMed 780G improved HbA1c and time in range in real-world diabetes data presented at ENDO 2026, with minimal hypoglycemia risk.

Stay updated with the latest healthcare breakthroughs, including data from ADA Scientific Sessions, a new CKM syndrome guideline, and more.

The FDA has cleared Dexcom's Stelo Glucose Biosensor System for over-the-counter use in children as young as 2 years who do not use insulin.

Teplizumab becomes the first disease-modifying therapy approved for patients recently diagnosed with stage 3 type 1 diabetes.

Catch up on any data and key clinician perspectives presented at the American Diabetes Association Scientific Sessions 2026.

Fonseca discusses substantially lower persistence and adherence with GLP-1s in real-world practice, highlighting methods for clinicians to address this.

This episode covers recently released data regarding the Dexcom G7 and Eli Lilly’s investigational triple agonist retatrutide from ADA 2026.

Shaminie Athinarayanan, PhD, discusses her recent study investigating the role of carbohydrate reduction in patients with obesity currently going through menopause.

Lance Sloan, MD, discusses his recent sub-analysis of the CATALYST trial, investigating whether hypercortisolism limits the efficacy of GLP-1s.

Amit Gupta, MBBS, DNB, joins the show to discuss diabetes treatment in a traditionally underserved population and to address the IDF’s work in moving it forward.

Sparrow Pharmaceuticals presented phase 2a data for the HSD-1 inhibitor clofutriben at ADA 2026.